Inhibition of Kaposi's Sarcoma in Vivo by Fenretinide
Overview
Authors
Affiliations
Purpose: We examined the effects of fenretinide [N-(4-hydroxyphenyl)retinamide; (4HPR)] on highly angiogenic Kaposi's sarcoma tumors in vivo and investigated the mechanisms involved for potential clinical applications.
Experimental Design: (CD-1)BR nude mice bearing KS-Imm cell tumors were randomized to receive 4HPR or vehicle until sacrifice. In vitro, KS-Imm and endothelial cells were treated with 4HPR to study the effects on proliferation, apoptosis, migration, and invasion; in vivo angiogenesis was evaluated in the Matrigel model. Angiogenesis-related and retinoid receptor molecules were examined at the mRNA and protein expression levels.
Results: In vivo, 4HPR significantly (P<0.001) reduced growth of detectable Kaposi's sarcoma (KS) xenografts and inhibited angiogenesis in the Matrigel plug assay (P<0.04). In vitro, 4HPR affected KS-Imm and endothelial cell growth and KS-Imm migration and invasion. 4HPR invasion inhibition was associated with decreased release of matrix metalloprotease-2 and rapid reduction of vascular endothelial growth factor (VEGF) expression by KS cells and of vascular endothelial growth factor receptor 2 (VEGFR2) by KS and endothelial cells. Finally, 4HPR repression of angiogenesis was associated with a 4HPR-induced increase in retinoic acid receptor beta expression.
Conclusions: These data indicate that 4HPR inhibits KS tumor growth in vivo through a mechanism involving the modulation of angiogenesis-associated growth factors and their receptors on both tumor and endothelial cells. In addition, 4HPR inhibited invasion by decreasing of matrix metalloprotease-2 activity. Our results justify further studies to evaluate the utility of 4HPR as a chemopreventive or therapeutic agent in KS, a malignancy associated with immune suppression that has a high risk of recurrence with highly active antiretroviral therapy failure.
The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review.
Ramchatesingh B, Martinez Villarreal A, Arcuri D, Lagace F, Setah S, Touma F Int J Mol Sci. 2022; 23(20).
PMID: 36293471 PMC: 9603842. DOI: 10.3390/ijms232012622.
Yucel E, Sahin M Mol Biol Rep. 2020; 47(3):1649-1658.
PMID: 31925643 DOI: 10.1007/s11033-020-05252-6.
Han B, Li S, Tong M, Holpuch A, Spinney R, Wang D Cancer Prev Res (Phila). 2015; 8(5):419-30.
PMID: 25712051 PMC: 4417376. DOI: 10.1158/1940-6207.CAPR-14-0418.
Zhang L, Zhou Q, Zhang N, Li W, Ying M, Ding W Cell Cycle. 2014; 13(8):1277-87.
PMID: 24608861 PMC: 4049964. DOI: 10.4161/cc.28190.
Conant K, Marinelli A, Kaleeba J Front Microbiol. 2013; 4:35.
PMID: 23487416 PMC: 3594938. DOI: 10.3389/fmicb.2013.00035.